PI3K/mTOR inhibitor LY3023414 in treating patients with relapsed or refractory advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/mTOR mutations (A pediatric match treatment trial). The gene discussed is TSC1; the disease is non-Hodgkin lymphoma.